onc brain

About · curated by Nick Boehling, MD · @nb2276

    2026-08-29

    digest generated 2026-09-15

    PROTEUS: 5-yr BCR-FS 44%, MFS 71%, CSS 92% at 60-mo median f/u in a real-world high-risk prostate cancer benchmark cohort.
    TL;DR
    Prostate is the only site today. PROTEUS gives a descriptive real-world benchmark for high-risk prostate cancer (5-yr BCR-FS 44%, MFS 71%, CSS 92%), meant to put perioperative strategies in context. It has no comparator arm. N, eligibility, treatment received and the high-risk definition are not in the source, so it sets a reference range, not a treatment effect.

    Prostate

    One descriptive high-risk benchmark and no randomised readout, so the 5-yr BCR-FS of 44% is a reference point for trial design, not a comparison.

    Unclear

    PROTEUS

    ForHigh-risk prostate cancer, perioperative setting

    TL;DR5-yr BCR-FS 44%, MFS 71%, CSS 92% at 60-mo median f/u in a real-world high-risk prostate cancer benchmark cohort.

    Also covered May 31

    7 details 1 trial watching
    Design

    Design not stated in source; described as a real-world benchmark. Median follow-up 60 mo.

    Endpoints

    Reported: 5-yr BCR-FS, 5-yr MFS, 5-yr CSS. No primary endpoint or effect size stated.

    Discussion

    Framed as a reference point for perioperative treatment strategies in high-risk disease, not a test of one. Useful only once the cohort definition and treatments received are known, since those determine which trial populations it can benchmark.

    Results
    Endpoint5-yr estimate
    BCR-FS44%
    MFS71%
    CSS92%
    Rationale

    Descriptive benchmark with no comparator, N, eligibility, or treatment details in source; cannot classify impact on any perioperative decision.

    Open questions

    Sourced from @CanDAydogdu

    📚 Sources · 🐦 1 tweet

    Surgery Curative Real-world evidence Unclear